Prescription PSE Law Would Cripple Sales, Push Costs – Industry Study
This article was originally published in The Tan Sheet
Executive Summary
Roughly 60 million people would not seek treatment for colds or allergies if prescriptions were required for pseudoephedrine products, reducing use by 83% and costing states an estimated $219.2 million in lost tax revenues over 10 years, a CHPA-backed study says. Proponents of an Rx approach say the costs caused by meth exceed that tax hit, and question the efficacy of other approaches to preventing diversion.
You may also be interested in...
GAO Backs Prescription Pseudoephedrine Approach
Senator Feinstein says PSE products should be available only by prescription nationwide. A GAO report supports “an expansion of prescription-only laws in the fight to combat the serious epidemic of meth production,” she says.
Electronic Tracking Success Could End Rx-Only Pseudoephedrine In Mississippi
Former Mississippi Gov. Haley Barbour says industry should ask state legislators to repeal the 2010 law that made all PSE drugs Rx-only. CHPA “might get some listeners” if it highlights how the tracking system places less of a financial burden on consumers and the health care system, he says.
Tennessee Emerges As PSE Battleground With Rx, NPLEx Proposals
The conflict between electronic tracking of pseudoephedrine purchases and shifting the drug ingredient to prescription-only status is elevated in Tennessee as lawmakers offer bills for both anti-methamphetamine strategies.